Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
The purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous administration of OTSA101-DTPA-90Y.
Relapsed or Refractory Synovial Sarcoma
DRUG: OTSA101-DTPA-111In|DRUG: OTSA101-DTPA-90Y
Pharmacokinetic (PK) and Biodistribution of OTSA101-DTPA-111In, Concentration of OTSA101-DTPA in plasma and the distribution of OTSA101-DTPA in the body by imaging scan will be assessed., up to 72 hours post dosing|Safety of OTSA101-DTPA-111In, This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria., up to 10 days post dosing|Safety of OTSA101-DTPA-90Y, This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria., up to 6 weeks post dosing
The purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous administration of OTSA101-DTPA-90Y.